dkn-01
mAbexperimental
Clinical trial activity
13 trials · 16 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
8
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2012 (NCT01457417)
Timeline
Indications
Studied for
- Bile Duct Neoplasms · Phase 1
- Biliary Tract Neoplasms · Phase 2
- Carcinoma, Hepatocellular · Phase 1/Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 1
- Carcinoma, Squamous Cell · Phase 1
- Carcinosarcoma · Phase 2
- Cholangiocarcinoma · Phase 1
- Colorectal Neoplasms · Phase 2
- Endometrial Neoplasms · Phase 2
- Esophageal Neoplasms · Phase 2
- Gallbladder Neoplasms · Phase 1
- Multiple Myeloma · Phase 1
- Neoplasms · Phase 1
- Ovarian Neoplasms · Phase 2
- Prostatic Neoplasms · Phase 1/Phase 2
- Stomach Neoplasms · Phase 2
- Uterine Neoplasms · Phase 2
Mechanism of action
- Dickkopf-related protein 1INHIBITOR
Dickkopf-related protein 1 inhibitor
Chemistry & pharmacology
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297562 ↗
Also known as
- dkn-01
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05761951 | Phase 2 | Aug 29, 2023 | Leap Therapeutics, Inc., Merck, National Cancer Institute (NCI), University of Texas at Houston |
| NCT05480306 | Phase 2 | Aug 30, 2022 | Leap Therapeutics, Inc. |
| NCT04363801 | Phase 2 | Jul 31, 2020 | BeOne Medicines, Leap Therapeutics, Inc., University of California, San Francisco |
| NCT03818997 | Phase 2 | Aug 31, 2019 | European Organisation for Research and Treatment of Cancer, Johannes Gutenburg University, Leap Therapeutics, Inc., Roche, Vall d'Hebron Institute of Research, Galatea Clinic |
| NCT04057365 | Phase 2 | Aug 31, 2019 | Bristol-Myers Squibb, Harvard University, Leap Therapeutics, Inc. |
| NCT03837353 | Phase 1/Phase 2 (Phase 2) | Mar 30, 2019 | Leap Therapeutics, Inc., New York University |
| NCT03645980 | Phase 1/Phase 2 (Phase 2) | Aug 31, 2018 | Johannes Gutenburg University, Leap Therapeutics, Inc. |
| NCT03395080 | Phase 2 | Feb 5, 2018 | Leap Therapeutics, Inc., University of Alabama, Birmingham |
| NCT02375880 | Phase 1 | Jun 1, 2015 | Leap Therapeutics, Inc. |
| NCT02013154 | Phase 1 | Jan 1, 2014 | Leap Therapeutics, Inc. |
| NCT01711671 | Phase 1 | May 1, 2013 | Leap Therapeutics, Inc., Theorem Clinical Research |
| NCT01457417 | Phase 1 | Jan 1, 2012 | Heatlhcare Pharmaceuticals, Leap Therapeutics, Inc. |
| NCT04681248 | N/A | — | Leap Therapeutics, Inc. |
Showing 13 of 13 trials
Page 1 / 1
Organizations
Research & Development (16)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Leap Therapeutics, Inc. | For profit | 13 | 8 | 3 | 2012 |
| Johannes Gutenburg University | Academic/Hospital | 2 | 1 | 1 | 2018 |
| BeOne Medicines | For profit | 1 | 0 | 1 | 2020 |
| Bristol-Myers Squibb | For profit | 1 | 0 | 1 | 2019 |
| European Organisation for Research and Treatment of Cancer | Academic/Hospital | 1 | 1 | 1 | 2019 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2019 |
| Heatlhcare Pharmaceuticals | For profit | 1 | 0 | 1 | 2012 |
| Merck | For profit | 1 | 0 | 1 | 2023 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2023 |
| New York University | Academic/Hospital | 1 | 1 | 1 | 2019 |
| Roche | For profit | 1 | 0 | 1 | 2019 |
| Theorem Clinical Research | For profit | 1 | 0 | 1 | 2013 |
| University of Alabama, Birmingham | Academic/Hospital | 1 | 0 | 1 | 2018 |
| University of California, San Francisco | Academic/Hospital | 1 | 0 | 1 | 2020 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Vall d'Hebron Institute of Research, Galatea Clinic | Academic/Hospital | 1 | 0 | 1 | 2019 |
16 organizations
Page 1 / 1